- Home
- ATXG vs ONCO Comparison
ATXG vs ONCO Comparison
Compare ATXG & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXG
- ONCO
- Stock Information
- Founded
- ATXG 2014
- ONCO 2018
- Country
- ATXG China
- ONCO United States
- Employees
- ATXG N/A
- ONCO N/A
- Industry
- ATXG Professional Services
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- ATXG Consumer Discretionary
- ONCO Health Care
- Exchange
- ATXG Nasdaq
- ONCO Nasdaq
- Market Cap
- ATXG 3.8M
- ONCO 4.3M
- IPO Year
- ATXG N/A
- ONCO 2022
- Fundamental
- Price
- ATXG $0.45
- ONCO $2.73
- Analyst Decision
- ATXG
- ONCO
- Analyst Count
- ATXG 0
- ONCO 0
- Target Price
- ATXG N/A
- ONCO N/A
- AVG Volume (30 Days)
- ATXG 374.7K
- ONCO 28.3K
- Earning Date
- ATXG 11-14-2025
- ONCO 12-09-2025
- Dividend Yield
- ATXG N/A
- ONCO N/A
- EPS Growth
- ATXG N/A
- ONCO N/A
- EPS
- ATXG N/A
- ONCO N/A
- Revenue
- ATXG $4,310,835.00
- ONCO $1,326,959.00
- Revenue This Year
- ATXG N/A
- ONCO N/A
- Revenue Next Year
- ATXG N/A
- ONCO N/A
- P/E Ratio
- ATXG N/A
- ONCO N/A
- Revenue Growth
- ATXG N/A
- ONCO N/A
- 52 Week Low
- ATXG $0.36
- ONCO $2.45
- 52 Week High
- ATXG $1.86
- ONCO $215.05
- Technical
- Relative Strength Index (RSI)
- ATXG 29.64
- ONCO 34.90
- Support Level
- ATXG $0.45
- ONCO $2.67
- Resistance Level
- ATXG $0.47
- ONCO $2.88
- Average True Range (ATR)
- ATXG 0.06
- ONCO 0.22
- MACD
- ATXG -0.02
- ONCO -0.11
- Stochastic Oscillator
- ATXG 4.92
- ONCO 3.03
About ATXG Addentax Group Corp.
Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.